Targeted Therapies Patient Forum September 2017 Speaker Highlight - John Cherol

dbrock's picture
Denise Brock, Operations Director

***Speaker Highlights***

for full faculty bio's, please visit our FACULTY page

 Learn about John Cherol, EGFR patient


*** update - John sadly passed away in January of 2018 at the very young age of 30. Our hearts are heavy with sadness.  Condolences to his loving family.***


John Cherol was diagnosed in January 2016 with Stage IV EGFR+ lung cancer at the age of 28. He started Gilotrif (afatinib) and acquired resistance after 14 months. Luckily a blood test showed he developed the t790m mutation and he started Tagrisso in April of this year. He’s also been treated for nine brain mets with Gamma Knife at the Cleveland Clinic.

John is a graduate of Youngstown State University with a bachelor’s degree in computer forensics.  He currently works as a Senior Cyber Security Analyst in Pittsburgh, PA. He got engaged shortly after his diagnosis to his fiancé, Kristine, who he met in 2014. They’re actively planning their September 9th wedding and a honeymoon to Iceland. Thanks to targeted therapy, John has been able to continue some of the hobbies he loves most like camping and kayaking. He hopes to help change the face of lung cancer and enjoy many more evening walks with Kristine and their rescue dog Liam.








Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation